Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response (MADDRE)

AstraZeneca

Status: Completed

Conditions: Major Depressive Disorder

Study type: Observational

Funder types: Industry

Identifiers

NCT01397903

NIS-NGR-XXX-2011/1

Details and patient eligibility

About

The purpose is to assess the response of add-on therapy, based on CGI-I scale, at 4 weeks, in patients with MDD who had an inadequate disease control with antidepressant medication.

Full description

A cross-sectional observational study to describe treatment management of patients with Major Depressive Disorder (MDD) and inadequate response to antidepressants in Greece

Enrollment: 545 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of MDD as per DSM-IV
• Patients with an inadequate disease control during antidepressant therapy
• Patients who already receive add-on therapy and have completed 4-5 weeks of treatment at the time of their enrolment in the study.

Exclusion criteria

• Patients fulfilling criteria for diagnosis of any other psychiatric condition (except for MDD), as per DSM-IV Axis I,
• Concomitant organic mental disorder or mental retardation Substance abuse or dependence (with the exception of nicotine dependence), as defined by DSM-IV criteria Participation in another study

Trial design

545 participants in 1 patient group

Group 1

Description:

Inpatients and outpatients diagnosed with major depressive disorder as per the DSM-IV criteria who had poor disease control during antidepressant treatment and have completed 4 weeks of add-on drug therapy at enrolment in the study. The percentage of patients with CGI-I score ≤ 2 at study Visit (4 weeks after the commencement of add-on treatment).